In Brief
This article was originally published in The Tan Sheet
Executive Summary
Dr. Reddy’s launches Allegra-D equivalent
You may also be interested in...
In Brief
Novartis OTC plant not “out of the woods”; ERSP questions Calmestra claims; GSK seeks to switch Pirinase Hayfever Relief to GSL in U.K.; Kaneka raises CoQ10 prices; FTC to disburse consumer refund for Iovate supplements; more In brief.
In Brief
Prestige Brands growth argues against Genomma bid; Abbott Nutrition refutes China research report; FDA expects annual doubling of supplement AERs; FTC settles with acai online marketers; Schiff Nutrition revises full-year sales growth guidance upward; more news In Brief.
Dr. Reddy’s Projects 50% Growth In U.S. OTC Business
The Indian private labeler predicts annualized U.S. OTC sales of $200 million by March 2013. Dr. Reddy’s recently launched an equivalent of Allegra-D 24 Hour and plans to introduce generic Prevacid 24HR in its next fiscal year.